Dominari (NASDAQ:DOMH) Trading Up 2.3% – What’s Next?

Dominari Holdings Inc. (NASDAQ:DOMH)’s share price rose 2.3% during trading on Monday . The company traded as high as $3.22 and last traded at $3.17. Approximately 110,744 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 266,336 shares. The stock had previously closed at $3.10.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Dominari from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Dominari currently has an average rating of “Sell”.

Dominari Price Performance

The firm has a market capitalization of $71.67 million, a price-to-earnings ratio of -0.79 and a beta of 0.80. The business has a fifty day moving average price of $3.14 and a two-hundred day moving average price of $3.64.

Dominari (NASDAQ:DOMH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($1.94). Dominari had a negative return on equity of 206.20% and a negative net margin of 31.37%.The firm had revenue of $35.81 million during the quarter, compared to analysts’ expectations of $35.81 million.

Dominari Dividend Announcement

The firm also recently disclosed a special dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were paid a dividend of $0.31 per share. The ex-dividend date was Friday, May 15th.

Institutional Trading of Dominari

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC lifted its stake in Dominari by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock valued at $361,000 after acquiring an additional 1,866 shares during the period. PFG Investments LLC lifted its stake in Dominari by 36.3% during the 1st quarter. PFG Investments LLC now owns 14,475 shares of the company’s stock valued at $47,000 after acquiring an additional 3,855 shares during the period. NewEdge Advisors LLC acquired a new stake in Dominari during the 4th quarter valued at approximately $50,000. Price T Rowe Associates Inc. MD acquired a new stake in Dominari during the 4th quarter valued at approximately $96,000. Finally, Oxford Asset Management LLP acquired a new stake in Dominari during the 4th quarter valued at approximately $120,000. 42.48% of the stock is currently owned by institutional investors and hedge funds.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.